Key result
Potent P-glycoprotein inhibitors increase levels and toxicity risk of narrow therapeutic index cardiovascular drugs.
Design
Review
Authors
Loading...
Clinicians must be aware of P-glycoprotein-mediated drug-drug interactions and consider dose adjustments or alternative agents when prescribing cardiovascular drugs with narrow therapeutic indexes alongside potent P-gp inhibitors.
Clinicians must be aware of P-glycoprotein-mediated drug-drug interactions and consider dose adjustments or alternative agents when prescribing cardiovascular drugs with narrow therapeutic indexes alongside potent P-gp inhibitors.
Wessler et al. (2013) conducted a review in Cardiovascular drug interactions. P-glycoprotein inhibitors and substrates was evaluated. Coadministration of cardiovascular drugs with narrow therapeutic indexes and potent P-glycoprotein inhibitors increases drug concentrations and the risk for drug toxicity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: